{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:10:40Z","timestamp":1779909040570,"version":"3.53.1"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Invitae Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,4,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Approximately 10% of pancreatic adenocarcinoma (PC) cases are attributed to hereditary causes. Individuals with PC and a personal history of another cancer associated with hereditary breast and ovarian cancer (HBOC) or Lynch syndrome (LS) may be more likely to carry germline mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Participants with PC and a history of cancer were selected from a pancreatic disease registry. Of 1296 individuals with PC, 149 had a relevant history of cancer. If banked DNA was available, a multigene panel was performed for individuals who had not 1) previously had a mutation identified through clinical testing or 2) undergone clinical multigene panel testing with no mutations detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010two of 124 individuals with PC and another HBOC\u2010 or LS\u2010related cancer who underwent genetic testing had a mutation identified in a PC susceptibility gene (18%). If prostate cancer is excluded, the mutation prevalence increased to 23% (21\/93). Mutation carriers were more likely to have more than 1 previous cancer diagnosis (<jats:italic>P<\/jats:italic> = .001), to have had clinical genetic testing (<jats:italic>P<\/jats:italic> = .001), and to meet National Comprehensive Cancer Network (NCCN) genetic testing criteria (<jats:italic>P<\/jats:italic> &lt; .001). Approximately 23% of mutation carriers did not meet NCCN HBOC or LS testing guidelines based on their personal cancer history and reported cancer history in first\u2010degree relatives.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>At least 18% of individuals with PC and a personal history of other HBOC\u2010 or LS\u2010related cancers carry mutations in a PC susceptibility gene based on our data, suggesting that criteria for genetic testing in individuals with PC should include consideration of previous cancer history. <jats:bold><jats:italic>Cancer<\/jats:italic> 2018;124:1691\u2010700<\/jats:bold>. \u00a9 <jats:italic>2018 American Cancer Society<\/jats:italic><\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.31242","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T11:33:11Z","timestamp":1516707191000},"page":"1691-1700","source":"Crossref","is-referenced-by-count":35,"title":["Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8464-6014","authenticated-orcid":false,"given":"Beth","family":"Dudley","sequence":"first","affiliation":[{"name":"Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Karloski","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico A.","family":"Monzon","sequence":"additional","affiliation":[{"name":"Castle Biosciences Incorporated Friendswood Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-7096","authenticated-orcid":false,"given":"Aatur D.","family":"Singhi","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Pittsburgh Medical Center Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Lincoln","sequence":"additional","affiliation":[{"name":"Invitae Corporation San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology University of Pittsburgh Medical Center Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall E.","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University of Pittsburgh Medical Center Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National Cancer Institute.Surveillance Epidemiology and End Results Program.https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed May 24 2017."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.02.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOGC.0000018821.48330.77"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.10.1394"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0194"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1358"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510123331504"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910640613"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171202"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0083"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204621"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000178"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_2_8_17_1","unstructured":"NCCN clinical practice guidelines in oncology: genetic\/familial high risk assessment: colorectal. Version 1.2017.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf. Published June 5 2017. Accessed July 31 2017."},{"key":"e_1_2_8_18_1","unstructured":"NCCN clinical practice guidelines in oncology: genetic\/familial high risk assessment: breast and ovarian. Version 2.2017.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf. Published December 12 2016. Accessed May 25 2017."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000439"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.04.009"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.37"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.6120"},{"key":"e_1_2_8_24_1","first-page":"5360","article-title":"Germline BRCA2 mutations in patients with apparently sporadic pancreatic carcinomas","volume":"56","author":"Goggins M","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0597-17"},{"key":"e_1_2_8_26_1","first-page":"409","article-title":"Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ\u2010line p16, BRCA1, and BRCA2 mutations","volume":"60","author":"Lal G","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_8_27_1","first-page":"3789","article-title":"Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%","volume":"62","author":"Murphy KM","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.3.214"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0783"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5546"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-009-9285-1"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2011-100281"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-011-9507-1"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3020"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7401"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.153"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29664"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.042"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0455"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-017-0019-5"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3502"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh288"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.12.025"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1902"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr933"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9661-5"},{"key":"e_1_2_8_47_1","unstructured":"US Food and Drug AdministrationFDA approves first cancer treatment for any solid tumor with a specific genetic feature.https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm560167.htm. Published May 23 2017. Accessed May 26 2017."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:25:42Z","timestamp":1760286342000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,15]]}},"alternative-id":["10.1002\/cncr.31242"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31242","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,23]]}}}